Cancer startup Anixa teams up with machine learning firm to seek out COVID-19 hopefuls

After delaying a CAR-T test and with time on its hands, Anixa Biosciences is working with Germany-based computational company OntoChem to find new antiviral meds for COVID-19.

It’s all very early-stage, but the pair hopes to tap into experimental antivirals in a speedy way to try to help kill off or at least dampen SARS-CoV-2, the virus causing the global COVID-19 pandemic.